Swiss Auto Components Stock News

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Helvetia...

Latest FY 2026 earnings snapshot Logitech International (SWX:LOGN) has just wrapped FY 2026 with fourth quarter revenue of US$1.1 billion and basic EPS of US$0.99, capping a year in which trailing twelve month revenue reached US$4.8 billion and EPS came in at US$4.85. Over the past two reported fourth quarters, revenue has moved from US$1,010.4 million to US$1,085.5 million while quarterly basic EPS shifted from US$0.97 to US$0.99. This gives a clearer view of how the top and bottom line are...

If you are wondering whether Sika at CHF147 is starting to look like value or still has more room to fall, the next sections will walk through what the current price actually reflects. The stock has risen 6.1% over the past week, but is still down 1.0% over the past month, 10.2% year to date and 30.7% over the past year, which may signal that investor sentiment and perceived risk have shifted several times. Recent coverage of Sika has focused on its position within the broader chemicals...

Compagnie Financière Tradition SA ( VTX:CFT ) stock is about to trade ex-dividend in 3 days. The ex-dividend date is...

In May 2026, Roche Holding and its Genentech unit presented new clinical data at the ASCO Annual Meeting, showcasing nine approved and investigational oncology medicines, with a particular emphasis on giredestrant in estrogen receptor-positive breast cancer across multiple disease stages. These data, including results from large Phase III trials such as lidERA and persevERA, underline Roche’s push to expand its breast cancer portfolio with targeted therapies that could reshape treatment...

Novartis (SWX:NOVN) plans to present extensive new data on late-stage cancer and immune disease therapies, including Pluvicto, Kisqali, Scemblix and ianalumab, at the 2026 ASCO and EHA congresses. The company is progressing treatments for rare conditions such as Charcot–Marie–Tooth disease alongside its broader oncology and hematology pipeline. Novartis is also participating in a major AI industry summit, highlighting its focus on digital tools across research and development. For investors...

Recent share performance and business scale Nestlé (SWX:NESN) has drawn fresh investor attention after a recent stretch of mixed returns, with the stock up over the past month but down over the past 3 years and past 5 years. The company closed at CHF 78.80, with a return of about 0.2% over the past day, 2.5% over the past week and 4.6% over the past month, while the share price declined about 2.6% over the past 3 months. Over longer periods, Nestlé’s total return is up about 3.1% year to date...

In recent weeks, ams-OSRAM completed a major debt refinancing, upsizing a €1 billion senior unsecured notes issue due 2032 and extending its €600 million revolving credit facility, while also inviting shareholders to a June 10, 2026 AGM that will vote on amendments to its Articles of Association and board mandates. An additional catalyst came from a J.P. Morgan upgrade that highlighted AI photonics and smart glasses as key long-term technology opportunities for ams-OSRAM. Against this...

As European markets grapple with geopolitical tensions and inflationary pressures, the pan-European STOXX Europe 600 Index recently saw a decline of 0.85%, reflecting broader economic concerns. Despite these challenges, robust earnings growth in certain sectors highlights opportunities for investors seeking stable income through dividend stocks. In such an environment, a good dividend stock is characterized by consistent payout history and strong fundamentals that can withstand market...

Lonza Group (SWX:LONN) has drawn fresh attention after shareholders approved a CHF 5.00 per share dividend, a 25% year-on-year increase, alongside board and remuneration committee changes at the 8 May 2026 Annual General Meeting. See our latest analysis for Lonza Group. Alongside the higher dividend and refreshed board, Lonza Group’s 1-day share price return of 0.92% and 7-day share price return of 3.86% come against a year-to-date share price return that is down 8.05%, and a 1-year total...

Züblin Immobilien Holding AG's ( VTX:ZUBN ) recent weak earnings report didn't cause a big stock movement. However, we...

Despite posting healthy earnings, Adecco Group AG's ( VTX:ADEN ) stock has been quite weak. Our analysis suggests that...

Sonova Holding (SWX:SOON) has just reported first half FY 2026 revenue of CHF1.8 billion and basic EPS of CHF3.16, alongside trailing twelve month revenue of CHF3.6 billion and EPS of CHF9.02 that sit against a mixed track record of earnings and margin trends. The company has seen first half revenue move from CHF1.8 billion in FY 2024 to CHF1.8 billion in FY 2025 and CHF1.8 billion in FY 2026, while basic EPS over those same first half periods shifted from CHF5.97 to CHF3.50 and then CHF3.16...

Roche Group (SWX:ROP) and Genentech plan to present new clinical data across nine cancer medicines at the 2026 ASCO Annual Meeting. The program includes breast cancer results that may be important for clinical practice, with a focus on giredestrant, a selective estrogen receptor degrader. Data span both investigational and approved therapies, including antibody drug conjugates, bispecific antibodies, and treatments for several cancer types. The breadth of readouts could influence treatment...

Barry Callebaut (SWX:BARN) has put product development in the spotlight at the 2026 Sweets & Snacks Expo by reshaping its compound range into a new Cacao Coatings & Inclusions category and launching Cacao Max and cocoa free ChoViva. See our latest analysis for Barry Callebaut. Investors have reacted positively to Barry Callebaut’s recent product announcements, with the share price delivering a 1 month share price return of 12.81% even though the 3 year total shareholder return is down 31.70%,...

Amrize AG ( VTX:AMRZ ) shareholders (or potential shareholders) will be happy to see that the CEO & Chairman, Jan...

Today is shaping up negative for Landis+Gyr Group AG ( VTX:LAND ) shareholders, with the analysts delivering a...

Sonova Holding AG has released its full-year results for the period ended March 31, 2026, reporting sales of CHF 3,605.9 million, net income of CHF 430.6 million, and announcing an annual dividend of CHF 4.70 per share payable on June 23, 2026. Despite lower reported net income year-on-year, the company achieved 5.9% sales growth and a 17.3% increase in normalized EBITA in local currencies, primarily driven by its Hearing Instruments segment and supported by business reshaping and the...

As European markets navigate the challenges of geopolitical tensions and inflationary pressures, investors continue to seek stability and growth through dividend stocks. In such a climate, selecting stocks with robust earnings growth and consistent dividend payouts can be an effective strategy for those looking to generate income while potentially mitigating volatility.

Novartis (SWX:NOVN) is back in focus after new clinical data showed its radioligand therapy Pluvicto, when added to standard treatment, cut the risk of PSA progression by 58% in a specific prostate cancer setting. See our latest analysis for Novartis. Alongside the Pluvicto data and a series of US manufacturing and research expansions, Novartis has seen firm investor interest, with the share price at CHF117.2 and an 8.02% year to date share price return, while the 1 year total shareholder...

Investors may be asking whether Swisscom at CHF676.0 is offering fair value right now, or if the recent momentum has already priced in the opportunity. The stock has returned 1.0% over the past week, 3.9% over the past month, 16.8% year to date, and 27.2% over the last year, which naturally raises questions about how much of its potential is already reflected in the price. Recent attention on Swisscom has focused on its role as a major Swiss telecom operator and how investors view its...

In early May 2026, Novartis broke ground on a new 46,000 sq. ft radioligand therapy manufacturing facility in Denton, Texas, part of its US$23.00 billion US manufacturing and research expansion and its fifth radioligand therapy site nationwide. This build-out of a coast-to-coast radioligand therapy network highlights how Novartis is tying manufacturing proximity and reliability directly to complex cancer treatment delivery for US patients. We will now explore how this expanded US radioligand...

Temenos (SWX:TEMN) is back in focus after a cluster of fresh contracts and product launches, including new core banking deals with Habib Bank Limited and Reliance Bank, as well as extended collaborations with First Abu Dhabi Bank and Questrade Financial Group. See our latest analysis for Temenos. The recent stream of banking deals and AI product launches comes against a mixed backdrop. The share price stands at CHF71.45, with a 90 day share price return of 11.29%, but a year to date share...

Adecco Group (SWX:ADEN) opened 2026 with Q1 revenue of €5.7b and basic EPS of €0.41, setting a clear benchmark for how the year is starting after a steady run of quarterly results. The company has seen revenue move from €5.6b in Q1 2025 to €5.7b in Q1 2026, while basic EPS over that same period went from €0.36 to €0.41. Trailing twelve month EPS of €1.81 provides a broader earnings backdrop. With net income of €69m in the quarter and a net profit margin of 1.3%, the story now is how...